Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 5/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 5/20 | 0.53 |
| ▸ | RELA | Q04206 | 5/20 | 0.53 |
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1078254 | 1.00 | NFKB1 (0.53) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL4274302 | 1.00 | NFKB1 (0.53) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL12951153 | 1.00 | NFKB1 (0.53) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL4951462 | 1.00 | NFKB1 (0.53) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL605621 | 1.00 | NFKB1 (0.53) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL605148 | 1.00 | NFKB1 (0.53) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL5270119 | 1.00 | NFKB1 (0.53) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL605147 | 1.00 | NFKB1 (0.53) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL15215795 | 0.87 | NFKB1 (0.53) | NFKB1NFKB2RELABTKKDM1A | |
| SCHEMBL19337828 | 0.86 | NFKB1 (0.51) | NFKB1NFKB2RELABTKKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035335-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250313524-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-10-09 | — | — | US | disclosed |
| EP-4522583-A2 | PI3K ALPHA INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-119486992-A | PI3K alpha inhibitors and methods of use thereof | 传达治疗有限公司 | 2025-02-18 | — | — | CN | disclosed |
| WO-2023220131-A2 | PI3Kα INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-2448916-B1 | PRODUCTION OF TRANS-4-AMINOCYCLOPENT-2-ENE-1-CARBOXYLIC ACID DERIVATIVES | REDDYS LAB LTD DR (IN) | 2014-09-03 | — | — | EP | disclosed |
| US-8524943-B2 | Production of trans-4-aminocyclopent-2-ene-1-carboxylic acid derivatives | DR. REDDY'S LABORATORIES, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120101297-A1 | PRODUCTION OF TRANS-4-AMINOCYCLOPENT-2-ENE-1-CARBOXYLIC ACID DERIVATIVES | DR. REDDY'S LABORATORIES, INC. (US) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313524-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | PIK3CA, PIK3CB, PIK3CD | NFKB1 1350/4885NFKB2 986/4885RELA 871/4885 |
| US-20260035335-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | PIK3CD, PIK3CG, PIK3CB | NFKB1 3120/4885NFKB2 2987/4885RELA 3547/4885 |
| US-20120101297-A1 | PRODUCTION OF TRANS-4-AMINOCYCLOPENT-2-ENE-1-CARBOXYLIC ACID DERIVATIVES | COASY, BCAT1, ALDH7A1 | NFKB1 1427/4885NFKB2 2293/4885RELA 2244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.